The FDA has greenlighted selpercatinib, the first targeted therapy for RET-altered non–small cell lung cancer (NSCLC) and certain types of thyroid cancer. Another RET inhibitor, pralsetinib, has been submitted for approval to treat NSCLC. Both drugs have shown effectiveness in treating brain metastases.

©2020 American Association for Cancer Research.
2020
American Association for Cancer Research.
You do not currently have access to this content.